New insulin candidate tested in 1,040 chinese diabetes patients
NCT ID NCT05834868
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new insulin called THDB0206 against a standard insulin (lispro) in 1,040 Chinese adults with type 2 diabetes. Both were used alongside a long-acting insulin. The goal was to see if the new insulin works as well or better at controlling blood sugar over 26 weeks. Participants had diabetes for at least 6 months and were already on insulin therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?